Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 3
Submit an article Journal homepage
81
Views
0
CrossRef citations to date
0
Altmetric
Review

Present State of Target Therapy for Disseminated Renal Cell Carcinoma

Sandra Waalkes1 Department of Urology & Urologic Oncology, Hannover University Medical School, Carl-Neuberg-Straße 1, 30625Hannover1, Germany
,
Mario Kramer1 Department of Urology & Urologic Oncology, Hannover University Medical School, Carl-Neuberg-Straße 1, 30625Hannover1, Germany
,
Thomas RW Herrmann1 Department of Urology & Urologic Oncology, Hannover University Medical School, Carl-Neuberg-Straße 1, 30625Hannover1, Germany
,
Andres J Schrader2 Department of Urology, Philipps-University Medical School, Marburg, Germany
,
Markus A Kuczyk1 Department of Urology & Urologic Oncology, Hannover University Medical School, Carl-Neuberg-Straße 1, 30625Hannover1, GermanyCorrespondence[email protected]
&
Axel S Merseburger1 Department of Urology & Urologic Oncology, Hannover University Medical School, Carl-Neuberg-Straße 1, 30625Hannover1, Germany
Pages 393-398 | Published online: 10 May 2010

Bibliography

  • Pontes JE : Adjunctive treatment of renal cell carcinoma.Inter. Advan. Surg. Oncol.6 , 309–322 (1983).
  • Golimbu M , JoshiP, SperberA, TesslerA, Al-AskariS, MoralesP: Renal cell carcinoma: survival and prognostic factors.Urology, 27(4) , 291–301 (1986).
  • Silverberg E , LuberaJ: Cancer statistics, 1987.CA Cancer J. Clin.37(1) , 2–19 (1987).
  • Sandock DS , SeftelAD, ResnickMI: A new protocol for the followup of renal cell carcinoma based on pathological stage.J. Urol.154(1) , 28–31 (1995).
  • Motzer RJ , BanderNH, NanusDM: Renal-cell carcinoma.N. Engl. J. Med.335(12) , 865–875 (1996).
  • Rabinovitch RA , ZelefskyMJ, GaynorJJ, FuksZ: Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy.J. Clin. Oncol.12(1) , 206–212 (1994).
  • Schrader AJ , VargaZ, PfoertnerS, GoeldenU, BuerJ, HofmannR: Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.BJU Int.97(3) , 461–465 (2006).
  • Hudes G , CarducciM, TomczakPet al.: Temsirolimus, interferon α, or both for advanced renal-cell carcinoma.N. Engl. J. Med.356(22) , 2271–2281 (2007).
  • Motzer RJ , HutsonTE, TomczakPet al.: Sunitinib versus interferon α in metastatic renal-cell carcinoma.N. Engl. J. Med.356(2) , 115–124 (2007).
  • Figlin RA Hutson TE, Tomczak P: Overall survival with sunitinib versus interferon (IFN)-α as first-line treatment of metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.26(Suppl.) , 5024 (2008).
  • Escudier B , EisenT, StadlerWMet al.: Sorafenib in advanced clear-cell renal-cell carcinoma.N. Engl. J. Med.356(2) , 125–134 (2007).
  • Escudier B , EisenT, StadlerWMet al.: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial.J. Clin. Oncol.27(20) , 3312–3318 (2009).
  • Escudier B , SzczylikC, HutsonTEet al.: Randomized Phase II trial of first-line treatment with sorafenib versus interferon α-2a in patients with metastatic renal cell carcinoma.J. Clin. Oncol.27(8) , 1280–1289 (2009).
  • Johannsen M , FlorckenA, BexAet al.: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.Eur. Urol.55(6) , 1430–1438 (2009).
  • Escudier B , PluzanskaA, KoralewskiPet al.: Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial.Lancet370(9605) , 2103–2111 (2007).
  • Miller K , BergmannL, AlbersPet al.: Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma.Aktuelle Urol.38(4) , 328–330 (2007).
  • Atkins MB , HidalgoM, StadlerWMet al.: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.J. Clin. Oncol.22(5) , 909–918 (2004).
  • Eichelberg C , HeuerR, ChunFKet al.: Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.Eur. Urol.54(6) , 1373–1378 (2008).
  • Dudek AZ , ZolnierekJ, DhamA, LindgrenBR, SzczylikC: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.Cancer115(1) , 61–67 (2009).
  • Herrmann E , BiererS, GerssJ, KopkeT, HertleL, WulfingC: Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients.Oncology74(3–4) , 216–222 (2008).
  • Sablin MP , NegrierS, RavaudAet al.: Sequential sorafenib and sunitinib for renal cell carcinoma.J. Urol.182(1) , 29–34; discussion 34 (2009).
  • Tamaskar I , GarciaJA, ElsonPet al.: Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.J. Urol.179(1) , 81–86; discussion 86 (2008).
  • Zimmermann K , SchmittelA, SteinerUet al.: Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.Oncology76(5) , 350–354 (2009).
  • Flanigan RC , SalmonSE, BlumensteinBAet al.: Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer.N. Engl. J. Med.345(23) , 1655–1659 (2001).
  • Mickisch GH , GarinA, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286) , 966–970 (2001).
  • Flanigan RC , YonoverPM: The role of radical nephrectomy in metastatic renal cell carcinoma.Semin. Urol. Oncol.19(2) , 98–102 (2001).
  • Szczylik C , PortaC, BracardaS: Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC).J. Clin. Oncol.26(Suppl.) , 5124 (2008).
  • Motzer RJ , MazumdarM, BacikJ, BergW, AmsterdamA, FerraraJ: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.J. Clin. Oncol.17(8) , 2530–2540 (1999).
  • Escudier BJ , BellmuntJ, NegrierSet al.: Final results of the Phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC).J. Clin. Oncol.27(Suppl.) , 5020 (2009).
  • Kay A , EscudierB, OudardSet al.: Updated data from a Phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). Presented at: ASCO Genitourinary Cancers Symposium 2009. Orlando, FL, USA, 26–28 February 2009.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.